Paraza Pharma is a Montréal drug discovery company focused on small-molecule therapeutics for immunology, inflammation, and cancer-related targets. Public materials describe an integrated discovery model that combines medicinal chemistry, biology, DMPK, and translational capabilities to advance proprietary and partnered programs. The company has been active in building candidate pipelines around high-value targets that can progress toward preclinical and clinical development.